CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
HIV shedding in the female genital tract of women on ART and progestin contraception: Extended follow-up results of a randomized clinical trial
-
June 01 2019
-
-
Source: J Acquir Immune Defic Syndr. 81(2):163-165
[PDF-49.57 KB]
Details:
-
Alternative Title:J Acquir Immune Defic Syndr
-
Personal Author:
-
Description:Background:
Progestin contraception has been linked to higher risk of female to male sexual HIV transmission.
Setting:
A clinical trial among HIV-infected women in Lilongwe, Malawi, randomized to initiation of depomedroxyprogesterone acetate (DMPA) injectable or levonorgestrel (LNG) implant, and followed for up to 33 months, with the outcome of HIV shedding in the genital tract.
Methods:
We compared the frequency and magnitude of HIV genital shedding before and after initiation of contraception and between study arms among women receiving antiretroviral therapy (ART). Genital HIV RNA was measured in TearFlo Strips using the Abbott RealTime HIV-1 assay.
Results:
Among 68 HIV-infected Malawian women on ART, randomization to DMPA compared with the LNG implant was not associated with genital shedding, and neither progestin contraceptive was associated with increased HIV genital shedding, for up to 33 months after contraceptive initiation. Having detectable plasma HIV (adjusted RR 10.5; 95% CI 3.18–34.7) and detectable genital shedding prior to contraceptive initiation (adjusted RR 3.53; 95% CI 1.31–9.47) were associated with a higher risk of detectable genital shedding after contraceptive initiation. Higher plasma efavirenz concentrations were associated with a lower risk of detectable genital shedding (adjusted RR 0.85; 95% CI 0.73–0.99, per increase of 1,000 ng/ml).
Conclusion:
Among HIV-infected women receiving ART, our results provide evidence that progestin contraception does not impact women’s risk of transmission of HIV to partners. Our finding that detectable genital shedding prior to contraceptive initiation independently predicts shedding suggests that there may be other individual level biological or behavioral factors that increase the risk for shedding.
Summary:
Among 68 HIV-infected Malawian women on ART, randomization to DMPA compared with the LNG implant was not associated with genital shedding, and neither progestin contraceptive was associated with increased HIV genital shedding, for up to 33 months after, compared to before,contraceptive initiation. Having detectable plasma HIV (adjusted RR 10.5; 95% CI 3.18–34.7) and detectable genital shedding prior to contraceptive initiation (adjusted RR 3.53; 95% CI 1.31–9.47) were associated with a higher risk of detectable genital shedding after contraceptive initiation, and higher plasma efavirenz concentrations were associated with a lower risk of detectable genital shedding (adjusted RR 0.85; 95% CI 0.73–0.99, per increase of 1,000 ng/ml).
-
Subjects:
-
Source:
-
Pubmed ID:31095006
-
Pubmed Central ID:PMC6527128
-
Document Type:
-
Funding:
-
Place as Subject:
-
Volume:81
-
Issue:2
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
